Drug intelligence / Profile preview

RZ-iMSN001

Development stage: Preclinical
Lead developer: Guangzhou Regenverse Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Implant

Overview

RZ-iMSN001 is an allogeneic induced pluripotent stem cell (iPSC)-derived cell therapy candidate being developed by Guangzhou Regenverse Therapeutics for the treatment of Huntington's disease. The therapy consists of a population of medium spiny neurons (MSNs) that are positive for DARPP-32 and CTIP2 markers. These cells are designed to be transplanted into the striatum to replace the MSNs that are progressively lost during the course of Huntington's disease. By restoring these neurons, RZ-iMSN001 aims to repair the cortical-basal ganglia neural circuits, specifically the indirect pathway, thereby potentially alleviating motor and cognitive symptoms. The program is currently in the preclinical stage, focusing on process development.

Beyond the preview

Go deeper on RZ-iMSN001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RZ-iMSN001.

Explore the full profile